HHS's 2026 draft peptide compounding policy, explained

Quick answer In a draft policy published for public comment on October 30, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500 when every condition is met, including a valid patient-specific prescription and a route the policy lists for that peptide. The draft is not final, and enforcement discretion is not approval: none of the six is FDA-approved, and as of October 2026 none is on FDA's 503A bulks list. HHS's draft says the policy would last until a final rule decides each peptide's status, and that it may revisit it if a safety signal or product quality issue arises.

What HHS did

HHS, the federal department FDA belongs to, has drafted a policy titled "HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The document carries no issue or effective date. The National Community Pharmacists Association, a pharmacists' trade group, reported it on October 29, 2026. HHS published it as a draft for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public."

Enforcement discretion is a statement about when an agency does not intend to act. Here the draft says HHS "does not intend to take enforcement action" against three kinds of compounder, a state-licensed pharmacy, a federal facility or a licensed physician, compounding a drug with one of six listed peptides, when all of the policy's conditions are met. It does not change the law, and it does not put any of the six on the list of ingredients licensed pharmacies may compound with.

The policy explains its own background. It is aimed at "research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients."

The six peptides and their routes

Each peptide is covered only by the routes the policy lists for it. Any route or form not listed isn't covered.

Emideltide (DSIP), the seventh peptide FDA's advisory committee reviewed in July 2026, is not covered. Neither is any peptide the policy doesn't name.

The conditions

As drafted, HHS's statement would apply only when every one of these is met:

1. A valid prescription for an individual patient. Compounding ahead of a prescription, or for resale, is outside the policy.
2. A tested ingredient from a registered maker. The bulk peptide has to come from a manufacturer registered with FDA under section 510 of the Federal Food, Drug, and Cosmetic Act that follows current good manufacturing practice, with a certificate of analysis covering identity, purity, potency, endotoxins, heavy metals, microbial contamination and impurities.
3. One active ingredient. A product combining two peptides, or a peptide with anything else active, isn't covered.
4. A plain label. It has to say "This is a compounded drug product. Not for resale."
5. Adverse-event reporting. Serious adverse events go to FDA's MedWatch program.
6. Evidence for oral forms. A form taken by mouth needs documented evidence of how well people absorb it that way (human oral bioavailability).
7. No other devices. The only device that may be packaged with it is a syringe FDA has cleared through its 510(k) process.

How a particular pharmacy meets these, and how a state board of pharmacy treats it, are questions for that pharmacy and its counsel.

How long it would last

As drafted, the policy would run until a final rule decides whether each peptide goes on the 503A bulks list. HHS says it may revisit the policy "in whole or in part" if "a safety signal or product quality issue arises." It is not a permanent authorization, and it can be narrowed or withdrawn. Before any of that, HHS is taking public comments on the draft, and its final version may differ.

What the policy is not

• Not final. It is a draft published for a two-week public comment period, and the Federal Register notice says it is "not binding on HHS or the public."
• Not FDA approval. In HHS's words, compounded drugs "are not FDA-approved." None of the six is an approved drug, and a compounded version would not be one either.
• Not a place on the bulks list. That list is a federal regulation, 21 CFR 216.23, changed only by notice-and-comment rulemaking. As of October 2026, none of the six is on it, and the Federal Register showed no proposed rule for any of them when last checked for these pages, on October 21, 2026.
• Not the July vote. FDA's Pharmacy Compounding Advisory Committee recommended six peptides on July 23 and 24, 2026, according to news reports, against the advice of FDA's own staff. That vote was advisory. The vote is explained here.
• Not an FDA category. FDA's interim Category 1, 2 and 3 are a separate system. How the categories work.
• Not cover for "research use only" products. The policy describes compounding for a patient on a prescription, not products sold for research.

A prescription vs "research use only"

The policy draws the line most people searching for these peptides need to see. On one side is a licensed pharmacy, federal facility or physician compounding for a named patient, on a prescription, from a tested ingredient made by an FDA-registered manufacturer, with a compounded-drug label and adverse-event reporting. On the other is a product labeled "research use only," sold without a prescription, with no pharmacy preparing it for you and nothing assuring you of what is in it.

In August 2026, FDA wrote to five online peptide sellers that a "research use only" label did not change its view when their websites showed the products were meant for people. The two routes are compared here.

Is this right for me?

This page explains a federal draft policy; it can't tell you whether any treatment suits your health. Only a licensed provider who knows your history can, and the answer may be no. Everlon doesn't offer any of the six peptides.

What you can do now:

• Read the page for the peptide you came here about. The table above links to each one, and BPC-157 vs TB-500 compares the two most often named together.
• Ask how each condition is met if a clinic offers one: the prescription, the route, the pharmacy's state license, the manufacturer's FDA registration and certificate of analysis, and the label.
• Take your goal to your own doctor, who can go through approved options.
• Pass on "research use only" products. Safety information below explains why.

How it works

1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
2. Hear from us only if Everlon offers one of them. We write about availability and nothing else, and you can unsubscribe anytime.
3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers one, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is BPC-157 legal now? It is still not FDA-approved and, as of October 2026, still not on FDA's 503A bulks list. What changed is that HHS has published a draft policy, open for public comment and not final, saying it does not intend to take enforcement action against BPC-157 compounded by a state-licensed pharmacy, federal facility or licensed physician when every condition is met, by a subcutaneous, intramuscular, oral or topical route. BPC-157's full status.

Can a doctor prescribe TB-500? The draft policy assumes a valid prescription for an individual patient, and would cover TB-500 compounded for subcutaneous or intramuscular injection when every other condition is met. It is a draft, not final. A prescription doesn't make it FDA-approved, and a form by any other route isn't covered.

Is Semax nasal spray allowed? Intranasal is the only route the draft policy lists for Semax. The draft, which is open for comment and not final, says HHS does not intend to take enforcement action against intranasal Semax compounded under all of its conditions; an injected form isn't covered. Semax is still not FDA-approved.

Does this mean FDA approved these peptides? No. HHS's draft policy says compounded drugs are not FDA-approved, and none of the six is an approved drug. The draft is about enforcement, not approval, and it is not final.

What isn't covered? Emideltide (DSIP) and any peptide the policy doesn't name; any of the six by a route the policy doesn't list for it; products that combine more than one active ingredient; and "research use only" products sold without a prescription.

How long would the policy last? As drafted, until a final rule decides each peptide's place on FDA's bulks list. It is still a draft: HHS is taking public comments for two weeks after the October 30, 2026 notice, and says it may revisit the policy in whole or in part if a safety signal or product quality issue arises, so it can change before then.

What this means for you

As of October 2026, none of these six peptides is on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against them when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.

The July 2026 FDA peptide vote, explained covers how the six got here.

Safety information

None of the six peptides is an FDA-approved drug, and compounded medications are not FDA-approved either, including anything compounded under this draft policy. There is no FDA-approved, labeled product to describe here.

What FDA has said about the six, on its safety page (current as of April 22, 2026):

• Immune reactions and impurities. For several of them, FDA says compounded drugs may pose a risk of immunogenicity (an immune reaction to the peptide) and may have peptide-related impurities.
• Little or no safety information. For BPC-157, Semax and Epitalon, FDA says it has identified no or limited safety information and lacks the information to know whether the drug would cause harm when given to people. For TB-500, MOTS-c and KPV, it says it has not identified any human exposure data.
• Not a verdict either way. These statements are not a finding that any of them is harmful, and not a finding that any of them is safe.

The policy's own conditions point at the same risks: a tested ingredient, a single active ingredient, and serious adverse events reported to FDA. Products sold online as "research use only" carry additional dangers: no licensed pharmacy makes them for a patient, so no pharmacy quality standards apply.

If you have used a product like this and feel unwell, stop and tell a doctor exactly what you took; you can also report it to FDA's MedWatch program. Seek care at once for trouble breathing, swelling of the face or throat, or a spreading rash. If this is a medical emergency, call 911.

Sources

• HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed). hhs.gov, accessed 2026-10-29
• National Community Pharmacists Association (NCPA). Newsroom report on enforcement discretion for compounding six peptides. October 29, 2026 (news report). ncpa.org, accessed 2026-10-29
• 21 U.S.C. 353a, Pharmacy compounding. law.cornell.edu, accessed 2026-10-06
• 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 05/14/2026). fda.gov, accessed 2026-10-21
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-21
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-21
• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026). fda.gov, accessed 2026-10-21
• Federal Register. Document search: "BPC-157", all agencies, newest first. federalregister.gov, accessed 2026-10-21 (through the Federal Register's public search API)
• FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
• AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026 (news report). ajmc.com, accessed 2026-10-06